menu search

Gbp/usd weekly outlook

GBP/USD’s strong rally and break of 1.2236 resistance confirms resumption of whole rebound from 1.203...

November 4, 2023, 2:21 pm

Target recovers from its 3-year low with key consumer trends, quarter results in spotlight

Target Corporation (NYSE:TGT) is up nearly 5% in the past five days as optimism builds on the stock. The gain overcame a losing streak that saw the st...

November 4, 2023, 10:07 am

1 under-the-radar stock that could triple by 2030

Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading candidates are currently in phase 2 cl...

November 4, 2023, 7:30 am

Investors sue solaredge technologies (sedg) for stocking up channels with excess inventory– hagens berman

Firm Encourages Investors with Losses to Contact its Attorneys SAN FRANCISCO, Nov. 03, 2023 (GLOBE NEWS...

November 4, 2023, 2:17 am

Rosen, a globally recognized law firm, encourages waldencast plc investors to inquire about securities class action investigation – wald, waldw

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, co...

November 4, 2023, 1:08 am

Clorox alert: bragar eagel & squire, p.c. is investigating the clorox company on behalf of clorox stockholders and encourages investors to contact the firm

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stock...

November 4, 2023, 1:00 am

Li-cycle alert: bragar eagel & squire, p.c. is investigating li-cycle, corp. on behalf of li-cycle stockholders and encourages investors to contact the firm

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stock...

November 4, 2023, 1:00 am

Dollar alert: bragar eagel & squire, p.c. is investigating dollar general corporation on behalf of dollar stockholders and encourages investors to contact the firm

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stock...

November 4, 2023, 1:00 am

Docgo alert: bragar eagel & squire, p.c. reminds investors that a class action lawsuit has been filed against docgo, inc. and encourages investors to contact the firm

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stock...

November 4, 2023, 1:00 am

R1 rcm alert: bragar eagel & squire, p.c. is investigating r1 rcm corp. on behalf of r1 rcm stockholders and encourages investors to contact the firm

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stock...

November 4, 2023, 1:00 am

Path final deadline: rosen, national trial lawyers, encourages uipath, inc. investors to secure counsel before important deadline in securities class action – path

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, re...

November 4, 2023, 1:00 am

Rosen, a leading law firm, encourages pacwest bancorp investors with losses in excess of $100k to secure counsel before important deadline in securities class action – pacw, pacwp

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, re...

November 4, 2023, 12:30 am

Investors sue barclays for inaccurately disclosing ex-ceo’s ties to jeffrey epstein – hagens berman

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Barclays PLC (BCS) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fra...

November 4, 2023, 12:22 am

Rosen, top ranked investor counsel, encourages tandem diabetes care, inc. investors to secure counsel before important deadline in securities class action – tndm

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, re...

November 4, 2023, 12:00 am

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. ...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. ...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. ...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. ...

November 3, 2023, 11:30 pm


Search within

Pages Search Results: